Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis (gMG) Naive to Complement Inhibitors. Prospective, Multicenter, Non-interventional Study (MG-ARCADIA).
Status: Recruiting
Location: See all (14) locations...
Intervention Type: Drug
Study Type: Observational
SUMMARY
The Polish multicentre observational (non-interventional) study aiming to collect data on the management and clinical outcomes of patients with gMG that received ravulizumab.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Adult (aged ≥18 years) patients with gMG, naive to complement inhibitors, receiving ravulizumab treatment in the frames of NDP in Poland.
• Patients willing to participate in the study and signed Informed Consent Form (ICF).
• Vaccination against N. meningitidis
Locations
Other Locations
Poland
Research Site
RECRUITING
Bydgoszcz
Research Site
RECRUITING
Gdansk
Research Site
NOT_YET_RECRUITING
Katowice
Research Site
RECRUITING
Katowice
Research Site
RECRUITING
Krakow
Research Site
RECRUITING
Lodz
Research Site
RECRUITING
Lublin
Research Site
WITHDRAWN
Poznan
Research Site
NOT_YET_RECRUITING
Poznan
Research Site
NOT_YET_RECRUITING
Szczecin
Research Site
RECRUITING
Szczecin
Research Site
RECRUITING
Warsaw
Research Site
NOT_YET_RECRUITING
Warsaw
Research Site
RECRUITING
Wroclaw
Contact Information
Primary
AstraZeneca Clinical Study Information Center
information.center@astrazeneca.com
1-877-240-9479
Time Frame
Start Date: 2025-05-15
Estimated Completion Date: 2029-12-31
Participants
Target number of participants: 50
Treatments
Ravulizumab
Open-lable arm with gMG patients who received ravulizumab treatment in the frames of NDP in Poland.
Related Therapeutic Areas
Sponsors
Leads: AstraZeneca